Innate Pharma S.A.
IPHANASDAQHealthcare● Active
$1.76
+$0.05(+2.92%)
Market Cap$165269787
P/E Ratio—
52W High$2.63
52W Low$1.17
Innate Pharma S.A. (IPHA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IPHA · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.79M | $12.62M | $51.90M | $57.67M | $12.11M |
| Cost of Revenue | $0.00M | $0.00M | $56.02M | $51.66M | $47.00M |
| Gross Profit | $2.79M | $12.62M | $5.62M | $6.01M | ($22.30M) |
| Gross Margin %(computed) | 100.00% | 100.00% | 10.83% | 10.42% | -184.12% |
| Operating Expenses | |||||
| R&D Expenses | $43.62M | $51.98M | $56.02M | $51.66M | $47.00M |
| G&A Expenses | $11.00M | $11.93M | $11.75M | $14.47M | $15.99M |
| Total Operating Expenses | $56.21M | $64.20M | $18.29M | $63.44M | $25.52M |
| Operating Income | ($53.42M) | ($51.58M) | ($12.67M) | ($57.42M) | ($47.83M) |
| Operating Margin %(computed) | — | -408.64% | -24.41% | -99.57% | -394.86% |
| Interest Income | $1.32M | $2.44M | $3.18M | $0.55M | $0.33M |
| Interest Expense | $0.44M | $0.57M | $0.64M | $0.29M | $0.31M |
| Income Before Tax | ($49.18M) | ($49.47M) | ($7.57M) | ($57.97M) | ($45.48M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($49.18M) | ($49.47M) | ($7.57M) | ($58.10M) | ($52.81M) |
| Net Margin %(computed) | — | -391.97% | -14.59% | -100.74% | -436.01% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.53 | $-0.61 | $-0.09 | $-0.73 | $-0.57 |
| Wtd Avg Shares | 89.42M | 81.05M | 84.11M | 79.59M | 79.54M |
| EBITDA | ($43.65M) | ($46.91M) | ($1.84M) | ($12.28M) | ($43.23M) |
| EBITDA Margin %(computed) | — | -371.69% | -3.54% | -21.29% | -356.91% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · EUR · M
Explore more Innate Pharma S.A. data
About Innate Pharma S.A. (IPHA) Income Statement
Innate Pharma S.A. (IPHA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, IPHA reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.05B) — a net profit margin of -1764.51%.
Frequently asked questions
IPHA · 4 questionsInnate Pharma S.A. (IPHA) reported revenue of $0.00B for 2025, down 77.9% year-over-year.
IPHA revenueIPHA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08